Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novo Nordisk A/S (NVO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
102.43 -0.77    -0.75%
08/08 - Closed. Currency in USD ( Disclaimer )
After Hours
102.31
-0.12
-0.12%
19:51:47 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,321,443
  • Bid/Ask: 99.80 / 103.65
  • Day's Range: 102.00 - 103.71
Novo Nordisk ADR 102.43 -0.77 -0.75%

NVO Income Statement

 
Featured here, the Income Statement (earnings report) for Novo Nordisk A/S, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2022
31/03
 2021
31/12
 2021
30/09
 2021
30/06
Total Revenue 42031 38333 35622 33041
Revenue 42031 38333 35622 33041
Other Revenue, Total - - - -
Cost of Revenue, Total 6917 6241 6059 5547
Gross Profit 35114 32092 29563 27494
Total Operating Expenses 22884 24699 20373 18262
Selling/General/Admin. Expenses, Total 11153 12822 10143 8905
Research & Development 5206 5632 4252 3944
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating - - - -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -392 4 -81 -134
Operating Income 19147 13634 15249 14779
Interest Income (Expense), Net Non-Operating -1228 -521 -137 138
Gain (Loss) on Sale of Assets - - - -
Other, Net - - - -
Net Income Before Taxes 17919 13113 15112 14917
Provision for Income Taxes 3709 2221 2993 2794
Net Income After Taxes 14210 10892 12119 12123
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 14210 10892 12119 12123
Total Extraordinary Items - - - -
Net Income 14210 10892 12119 12123
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 14210 10892 12119 12123
Dilution Adjustment - - - -
Diluted Net Income 14210 10892 12119 12123
Diluted Weighted Average Shares 2283.3 2320.5 2297.3 2306.3
Diluted EPS Excluding Extraordinary Items 6.22 4.69 5.28 5.26
DPS - Common Stock Primary Issue - 3.6 - 5.78
Diluted Normalized EPS 6.22 4.69 5.28 5.26
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
ramu g
ramu g Aug 03, 2022 11:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
novo very expensive drug market hemophilia drug big profitible business
Reply
0 0
Report
Asterix Hr
Asterix Hr Dec 15, 2021 7:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
Reply
0 0
Report
daemin jeong
daemin jeong Nov 02, 2021 5:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
sure, best company
Reply
1 0
Report
David Dahan
David Dahan May 24, 2021 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
NVO WILL BUY ORMP AT 30 $
Reply
1 0
Report
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
and Gals..! :D
Reply
1 0
Report
Petri Kiljunen
Petri Kiljunen Feb 16, 2021 10:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
Reply
2 1
Report
Ralf Adams
Ralf Adams Feb 16, 2021 10:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
Reply
1 0
Report
Naim West
Naim West Feb 16, 2021 10:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Could be massive?? It will be now approved by FDA in US and soon EU all that remains is production cabability which was surprisingly not ready for such a demand (only US) so IMO this WILL exploded 10 fold what NN has expected., maybe more. Where do you find a obesity drug that helps? What obesity formulars has ever worked? This actually dos work.. Get ready!!!
Reply
0 0
Report
christopher brown
christopher brown Aug 01, 2019 1:08PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Very good long term investment
Reply
6 0
Report
Jorgen Andersen
Jorgen Andersen Feb 06, 2019 4:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone got a view on how much the plans to reduce medical prices will affect the share price ?
Reply
1 0
Report
Jens Kramer
Jens Kramer Feb 06, 2019 4:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
My bet is that the stock price will have an increase in growth on the long term. Not sure about short term as they might need to spend to expand production, however, they might get subsidies for this.
Reply
2 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email